Stock comparison
Halozyme Therapeutics
Sanofi
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HALO
Halozyme Therapeutics
Market cap
$8.1B
Sector
Healthcare
SNY
Sanofi
Market cap
$106.67B
Sector
Healthcare
Overall winner
Halozyme Therapeutics HALO
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HALO | SNY | Winner |
|---|---|---|---|
| Warren Buffett | 79B | 61C | HALO |
| Benjamin Graham | 83A | 40D | HALO |
| Philip Fisher | 65B | 53C | HALO |
| Peter Lynch | 53D | 39D | HALO |
| Joel Greenblatt | 40D | 39D | HALO |
| Charlie Munger | 80C | 48D | HALO |
| Terry Smith | 84A | 49D | HALO |
Side-by-side metrics
| Metric | HALO | SNY |
|---|---|---|
| Market cap | $8.1B | $106.67B |
| P/E (TTM) | 24.0x | 8.6x |
| EV/EBIT | 10.2x | 10.8x |
| ROIC (TTM) | 23.65% | 11.66% |
| Gross margin | 81.24% | 71.62% |
| Net margin | 23.13% | 17.59% |
| Revenue CAGR 5y | 33.23% | 4.5% |
| EPS CAGR 5y | -1.98% | 6.47% |
| Debt / Equity | 1.0x | 0.3x |
| Dividend yield | 0.0% | 5.57% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HALO leads on
- Revenue CAGR 5y33.23%vs 4.5%+86%
- ROIC (TTM)23.65%vs 11.66%+51%
- Net margin23.13%vs 17.59%+24%
- Gross margin81.24%vs 71.62%+12%
SNY leads on
- EPS CAGR 5y6.47%vs -1.98%+131%
- Dividend yield5.57%vs 0.0%+100%
- Market cap$106.67Bvs $8.1B+92%
- Debt / Equity0.3xvs 1.0x+71%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.